Toll Free: 1-888-928-9744

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction - Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Bowel Dysfunction (Toxicology) pipeline landscape.

Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-oesophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Bowel Dysfunction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Bowel Dysfunction (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

Opioid-Induced Bowel Dysfunction (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (Toxicology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Bowel Dysfunction (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Opioid-Induced Bowel Dysfunction (OBD or OIBD) Overview 6 Therapeutics Development 7 Pipeline Products for Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview 7 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics under Development by Companies 8 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Products Glance 9 Early Stage Products 9 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Products under Development by Companies 10 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development 11 ChironWells GmbH 11 Orphomed Inc 12 RaQualia Pharma Inc 13 Vitality Biopharma Inc 14 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Target 16 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 23 ORP-102 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 ORP-106 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 RQ-00433412 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecule to Antagonize Mu Opioid Receptor for Gastrointestinal Disorders - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 VB-100 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 VB-210 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31
List of Tables
Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Early Stage Development, H2 2016 9 Products under Development by Companies, H2 2016 10 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by ChironWells GmbH, H2 2016 11 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by Orphomed Inc, H2 2016 12 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by RaQualia Pharma Inc, H2 2016 13 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by Vitality Biopharma Inc, H2 2016 14 Assessment by Monotherapy Products, H2 2016 15 Number of Products by Stage and Target, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 22 Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects, H2 2016 29



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify